Biogen's revenue has shrunk by 6.0% a year over the last 5 years; the median of the Health Care sector is +8.5%. The net margin in the last fiscal year was 13.1%, the sector median 13.9%. The 52-week high is 4.6% away (close of Nov 20, 2026).
Metrics from daily candles, as of Nov 20, 2026
· Extended universe
Live quote by TradingView
One click loads all TradingView content on this page. Data (including your IP address) is sent to TradingView, also to the USA. Privacy
Prices: TradingView (stock prices delayed).
Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year
At a glance: figures and chart
3 strengths · 3 weaknesses · Fiscal year to Dec 31, 2025
Quality checks from the annual figures and, separately, the position of the price relative to the 200-day line. No overall score.
Quality6 of 7 criteria with data met · 1 without data
Growth1 of 7 criteria with data met
Dividend0 of 1 criteria with data met · 6 without data
Financial strength5 of 6 criteria with data met
Chart positionbelow200-day lineabovemore than 10% above – position relative to the 200-day line
Strengths well above the threshold
+Gross margin75.7%Threshold: above 40% · Distance +35.7 pp · Sector median 61.8% (49 stocks) · Fiscal year to Dec 31, 2025
+Free cash flow margin20.7%Threshold: above 10% · Distance +10.7 pp · Sector median 14.5% (61 stocks) · Fiscal year to Dec 31, 2025
+Equity ratio62.0%Threshold: above 30% · Distance +32.0 pp · Sector median 44.2% (63 stocks) · Fiscal year to Dec 31, 2025
Weaknesses well below the threshold
−Return on equity7.1%Threshold: above 15% · Distance −7.9 pp · Sector median 12.8% (54 stocks) · Fiscal year to Dec 31, 2025
−Revenue growth 5 years−6.0% per yearThreshold: above 5% per year · Distance −11.0 pp · Sector median +7.8% per year (60 stocks) · Fiscal year to Dec 31, 2025
−Piotroski F-Score5 of 9Threshold: at least 7 · Distance −2 points · Sector median 6 of 9 (47 stocks) · Fiscal year to Dec 31, 2025
On the radar
Position relative to the 200-day line: more than 10% above (as of Nov 20, 2026)
What we do not know
Data missing: 1 of 28 criteria not stated in the SEC filings (Fiscal year to Dec 31, 2025).
Operating margin above 15%
Not applicable
Pays no dividend – the dividend criteria do not apply (Fiscal year to Dec 31, 2025).
How is this made? · Created on Nov 22, 2026 from fixed rules · not investment advice
Load chart from TradingView
This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.
Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself.Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself.Academy: 200-day line · RSI
About the company
Biogen is a biotechnology company from Massachusetts focused on diseases of the nervous system. It offers drugs for multiple sclerosis and spinal muscular atrophy (Spinraza) and markets the Alzheimer’s drug Leqembi with Eisai. As of Oct 11, 2026
As of Oct 11, 2026Fact sheet (from the annual report)Biotechnology and vaccines · Cambridge, USAfull fact sheet
According to the company, the group is a global biopharmaceutical company focused on neurology, specialized immunology and rare diseases. For multiple sclerosis it markets TYSABRI, TECFIDERA, VUMERITY and AVONEX, and for spinal muscular atrophy SPINRAZA. Other products are SKYCLARYS for Friedreich’s ataxia and QALSODY for a genetic form of ALS. Together with Eisai the group markets LEQEMBI for a form of dementia and, with Supernus, the drug ZURZUVAE. TYSABRI and SPINRAZA each accounted for a material share of total revenue in 2025. In November 2025 the group acquired Alcyone Therapeutics, and in 2025 it gave up its rights to TOFIDENCE and BYOOVIZ.
This symbol belongs to the extended universe: we load daily candles only and show metrics, fundamentals and an overview – chart methods and Elliott analysis are not available for it.
Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze
Price performance at a glance
Last 30 trading days
Today+1.0%
7 days−1.5%
30 days+3.6%
1 year+48.4%
Day range (last trading day)
−0.6%Price at 31% of the range+1.4%
52-week range
−35.8%Price at 89% of the range+4.6%
Distance from the all-time high
−48.0%
Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Chart analysis: trend by timeframe
Trend by timeframeFor each timeframe (week, day, 4 hours): up when the close is above the SMA 200, the EMA 20 above the EMA 50 and the structure shows higher highs and lows. Down the other way round, otherwise mixed. No score, no forecast.Example: Week up, day up, 4 hours mixed → not aligned.More in the Academy: Lesson trend and market structure
1Wweekly candles↗ up
Close above the SMA 200
EMA 20 above the EMA 50
higher highs and higher lows
Price above the EMA 20 · above the EMA 50
Week to Nov 20, 2026
1Ddaily candles↔ mixed
Close above the SMA 200
EMA 20 above the EMA 50
lower highs and lower lows
Price above the EMA 20 · above the EMA 50
Daily candle of Nov 20, 2026
4H4-hour candles– not available
No value on 4 hours (too few or no checked 4-hour candles).
Rule per timeframe: up = close above the SMA 200, EMA 20 above the EMA 50 and higher highs and lows; down = everything the other way round; otherwise mixed. Completed candles only, no overall score, no forecast. In the screener: all three up →
What does the daily chart show right now – line by line, without an overall verdict?
Technicals in plain words
Technicals in plain wordsFour lines on the daily chart – trend, momentum, volume, volatility –, each with its metric and threshold. We do not add the lines up or give a grade; they describe the price history so far.Example: RSI 64 → between 30 and 70, neither overbought nor oversold.More in the Academy: Lesson reading the RSI
Over the last 3 months it ran stronger than the S&P 500 and stronger than the median of the sector “Health Care”.
vs. S&P 500 · 3 monthsRelative strengthA stock’s price change minus that of the benchmark over the same period, in percentage points: against the S&P 500 (ETF SPY) or the median of its sector, over 3 or 6 months. Above 0 it ran stronger, below 0 weaker – this describes the past.Example: Stock +12%, S&P 500 +5% in 3 months → +7 percentage points, ran stronger.More in the Academy: Lesson relative strength
stronger
vs. S&P 500 · 6 monthsRelative strengthA stock’s price change minus that of the benchmark over the same period, in percentage points: against the S&P 500 (ETF SPY) or the median of its sector, over 3 or 6 months. Above 0 it ran stronger, below 0 weaker – this describes the past.Example: Stock +12%, S&P 500 +5% in 3 months → +7 percentage points, ran stronger.More in the Academy: Lesson relative strength
stronger
vs. sector · 3 monthsRelative strengthA stock’s price change minus that of the benchmark over the same period, in percentage points: against the S&P 500 (ETF SPY) or the median of its sector, over 3 or 6 months. Above 0 it ran stronger, below 0 weaker – this describes the past.Example: Stock +12%, S&P 500 +5% in 3 months → +7 percentage points, ran stronger.More in the Academy: Lesson relative strength
stronger
Trendabove SMA 200Price above the 200-day line – above it the long-term trend counts as up; ADX between 20 and 25 – a moderate trend.
MomentumneutralRSI between 30 and 70 – neither overbought nor oversold; MACD line below its signal line (gap below 0).
Volumenot elevatedVolume on the last trading day below 1.5 times the average of up to 50 trading days before – not elevated.
VolatilitynormalTypical daily range (ATR 14) between 2 and 4% of the price – normal; Bollinger Bands as narrow as on at most one fifth of the last 120 trading days (squeeze).
The figures behind it – distance to the line, RSI, volume, volatility and relative strength in percentage points – are visible with a free account.Sign up free
More depth
How we read the lines
Each line stands on its own – we do not add them up and give no grade.
Trend: the 200-day line is the average of the last 200 closing prices. The ADX (14) measures how pronounced a trend is, not its direction: below 20 hardly any trend, above 25 pronounced.
Momentum: the RSI (14) lies between 0 and 100; below 30 it counts as oversold, above 70 as overbought. The MACD (12/26) compares two averages, the signal line (9) smooths it.
Volume: shares traded on the last trading day divided by the average of up to 50 trading days before; from 1.5x elevated, from 2x unusually high, from 3x very high.
Volatility: typical daily range (ATR 14) as a percentage of the price; below 2% calm, 2 to 4% normal, above 4% high. Squeeze = Bollinger Bands as narrow as on at most a fifth of the last 120 trading days.
Relative strength: the stock’s price change minus that of the benchmark over the same period (3 months = 91 days, 6 months = 182 days), in percentage points, from completed daily candles. Benchmark: the S&P 500 (ETF SPY) or the median of the stocks of the same sector in our selection (at least 5 others with a candle on the same day). Dividends are not included.
Against the sector median over 6 months: ran stronger.
All figures describe the price history so far – they do not say what happens next.
As of: daily candle of Nov 20, 2026 · from our daily candles
How did this asset do in each calendar month over the last 10 years?
Seasonality
SeasonalityHow an asset did in each calendar month over the last 10 years: monthly return from the last trading day of the previous month to the last one of the month, without dividends, completed months only. Past performance, not a forecast.Example: Example: November higher in 7 of 10 years → describes past years, not the next November.More in the Academy: Lesson seasonality
In November, the stock closed higher in 6 of 10 years – the S&P 500 in 9 of 10.
Years higher in NovemberSeasonalityHow an asset did in each calendar month over the last 10 years: monthly return from the last trading day of the previous month to the last one of the month, without dividends, completed months only. Past performance, not a forecast.Example: Example: November higher in 7 of 10 years → describes past years, not the next November.More in the Academy: Lesson seasonality
6 of 10
2016 to 2025
S&P 500 in November
9 of 10
years higher, same years as above (ETF SPY)
Months mostly higher
5 of 12
Calendar months that closed higher in more than half of the years
You can see the median and range per month in percent with a free account.Sign up free
5/10Jan
3/10Feb
3/10Mar
2/10Apr
6/10May
6/10Jun
6/10Jul
6/10Aug
4/10Sep
4/10Oct
6/10Nov
3/10Dec
January: higher in 5 of 10 years
February: higher in 3 of 10 years
March: higher in 3 of 10 years
April: higher in 2 of 10 years
May: higher in 6 of 10 years
June: higher in 6 of 10 years
July: higher in 6 of 10 years
August: higher in 6 of 10 years
September: higher in 4 of 10 years
October: higher in 4 of 10 years
November (current month): higher in 6 of 10 years
December: higher in 3 of 10 years
Past performance, not a forecast · Bar = share of years higher, line = half · Price return without dividendsMore depth
How we calculate
Monthly return = closing price on the last trading day of the month ÷ closing price on the last trading day of the previous month − 1. Price return without dividends.
Only completed months count, never the current one. If the candle of the last trading day is missing, the month does not count.
For each calendar month the last 10 years in which it has ended; from 8 years with a value we show the median, years higher and the range. “Higher” means: return above 0.0%.
Past performance, not a forecast: the figures describe earlier years and do not tell how the next month will go.
By calendar month (● = current month)
Month
Years higher
January
5 of 10
February
3 of 10
March
3 of 10
April
2 of 10
May
6 of 10
June
6 of 10
July
6 of 10
August
6 of 10
September
4 of 10
October
4 of 10
November ●
6 of 10
December
3 of 10
Through October 2026 (last completed month) · from our daily candles
Fundamental analysis
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and margin
Biogen · Sector Health Care · amounts in USD
Source: SEC filings, As of Feb 6, 2026.
Investor typeInvestor type (“lens”)You choose which style comes first: dividends, valuation, growth, quality or trading. Screener and stock page then show suggestions and “For you first”, with an account also matching columns and order. The lens unlocks nothing and changes no matches.Example: Lens “Dividends” → on the stock page first the streak without a cut, growth and cover of the dividend.More in the Academy: Guide fundamental analysis
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
–no data: Operating margin above 15%not stated in the SEC filings
✓met: Net margin above 10%13.1%
✗not met: Return on equity above 15%7.1%
✓met: Free cash flow margin above 10%20.7%
✓met: Profit in each of the last 5 fiscal years5 of 5
✓met: Free cash flow positive in each of the last 3 fiscal years3 of 3
✓met: Equity ratio above 30%62.0%
Gross margin
75.7%Fiscal year 2025
All89strong
Rank 89 of 100: higher than 89% of 370 peers (All). strong.
Sector89strong
Rank 89 of 100: higher than 89% of 49 peers (Sector). strong.
Median Health Care: 61.8%
Share of revenue left after the direct cost of the products sold.
Net margin
13.1%Fiscal year 2025
All56medium
Rank 56 of 100: higher than 56% of 584 peers (All). medium.
Sector52medium
Rank 52 of 100: higher than 52% of 63 peers (Sector). medium.
Median Health Care: 12.9%
Profit after all costs, interest and taxes divided by revenue.
Return on equity
7.1%Fiscal year 2025
All26weak
Rank 26 of 100: higher than 26% of 544 peers (All). weak.
Sector25weak
Rank 25 of 100: higher than 25% of 54 peers (Sector). weak.
Median Health Care: 12.8%
Net income divided by equity at fiscal year end.
Return on assets
4.4%Fiscal year 2025 (total assets at year end)
All45medium
Rank 45 of 100: higher than 45% of 594 peers (All). medium.
Sector36medium
Rank 36 of 100: higher than 36% of 63 peers (Sector). medium.
Median Health Care: 6.6%
Net income divided by total assets at fiscal year end.
Equity ratio
62.0%Fiscal year 2025
All85strong
Rank 85 of 100: higher than 85% of 595 peers (All). strong.
Sector75strong
Rank 75 of 100: higher than 75% of 63 peers (Sector). strong.
Median Health Care: 44.2%
Equity as a share of total assets. Usually low for banks.
Free cash flow margin
20.7%Fiscal year 2025
All78strong
Rank 78 of 100: higher than 78% of 465 peers (All). strong.
Sector70strong
Rank 70 of 100: higher than 70% of 61 peers (Sector). strong.
Median Health Care: 14.5%
Free cash flow divided by revenue.
Free cash flow
2.1B USDFiscal year 2025
Operating cash flow minus capital expenditure on property and equipment.
Growth 1 of 7 met
✗not met: Over 3 years, revenue grew by more than 5% per year−0.9%
✗not met: Over 5 years, revenue grew by more than 5% per year−6.0%
✗not met: Over 10 years, revenue grew by more than 5% per year−0.8%
✗not met: Over 3 years, EPS grew by more than 5% per year−25.0%
✗not met: Over 5 years, EPS grew by more than 5% per year−18.7%
✗not met: Revenue rose in at least 4 of the last 5 fiscal years1 of 5
✓met: Revenue rose in the last fiscal year+2.2%
Revenue growth 3 years
−0.9%per year
All18weak
Rank 18 of 100: higher than 18% of 578 peers (All). weak.
Sector15weak
Rank 15 of 100: higher than 15% of 62 peers (Sector). weak.
Median Health Care: +5.1%
Average growth per year over 3 fiscal years.
Revenue growth 5 years
−6.0%per year
All2weak
Rank 2 of 100: higher than 2% of 549 peers (All). weak.
Sector1weak
Rank 1 of 100: higher than 1% of 60 peers (Sector). weak.
Median Health Care: +7.8%
Average growth per year over 5 fiscal years.
Revenue growth 10 years
−0.8%per year
All5weak
Rank 5 of 100: higher than 5% of 412 peers (All). weak.
Sector3weak
Rank 3 of 100: higher than 3% of 50 peers (Sector). weak.
Median Health Care: +9.3%
Average growth per year over 10 fiscal years.
EPS growth 3 years
−25.0%per year
All9weak
Rank 9 of 100: higher than 9% of 437 peers (All). weak.
Sector5weak
Rank 5 of 100: higher than 5% of 54 peers (Sector). weak.
Median Health Care: +5.0%
Growth of earnings per share per year, adjusted for stock splits.
EPS growth 5 years
−18.7%per year
All4weak
Rank 4 of 100: higher than 4% of 399 peers (All). weak.
Sector7weak
Rank 7 of 100: higher than 7% of 47 peers (Sector). weak.
Median Health Care: +8.3%
Growth of earnings per share per year, adjusted for stock splits.
EPS growth 10 years
−5.4%per year
All7weak
Rank 7 of 100: higher than 7% of 375 peers (All). weak.
Sector5weak
Rank 5 of 100: higher than 5% of 46 peers (Sector). weak.
Median Health Care: +9.3%
Growth of earnings per share per year, adjusted for stock splits.
Dividend 0 of 1 met · 6 without data
✗not met: Pays a dividendno dividend per share reported for the last fiscal year
–no data: Payout ratio at most 60% of earningspays no dividend
–no data: Dividend paid in each of the last 5 fiscal yearspays no dividend
–no data: Dividend per share never lowered in the last 5 fiscal yearspays no dividend
–no data: Dividend per share higher than 5 years agopays no dividend
–no data: Free cash flow per share covers the dividendpays no dividend
–no data: Dividends paid over the last 5 years covered by free cash flowpays no dividend
Financial strength 5 of 6 met
✗not met: Piotroski F-Score at least 7 of 95 of 9
✓met: Long-term debt no higher than equity0.34
✓met: Current assets cover current liabilities2.68
✓met: Positive equity18.3B USD
✓met: In 5 years, share count up by at most 5%−8.8%
✓met: Free cash flow positive in the last fiscal year2.1B USD
Piotroski F-Score
5 of 9Fiscal year 2025
All22weak
Rank 22 of 100: higher than 22% of 310 peers (All). weak.
Sector17weak
Rank 17 of 100: higher than 17% of 47 peers (Sector). weak.
Median Health Care: 6.0 of 9
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
Debt / equity
0.34at fiscal year end
All74strong
Rank 74 of 100: lower than 74% of 486 peers (All). strong.
Sector77strong
Rank 77 of 100: lower than 77% of 50 peers (Sector). strong.
Median Health Care: 0.66
Long-term financial debt divided by equity.
Liquidity (current ratio)
2.68at fiscal year end
All82strong
Rank 82 of 100: higher than 82% of 513 peers (All). strong.
Sector77strong
Rank 77 of 100: higher than 77% of 63 peers (Sector). strong.
Median Health Care: 1.58
Current assets divided by current liabilities.
Change in share count
−8.8%in 5 years
All71strong
Rank 71 of 100: lower than 71% of 507 peers (All). strong.
Sector72strong
Rank 72 of 100: lower than 72% of 59 peers (Sector). strong.
Median Health Care: −4.3%
Change in diluted share count. Negative = share buybacks, positive = new shares.
The 9 criteria of the Piotroski F-Score
✓met: Profit in the last fiscal year (positive return on assets)
✓met: Positive operating cash flow
✗not met: Return on assets higher than the prior year
✓met: Operating cash flow higher than net income
✓met: Long-term debt relative to total assets fell
✓met: Liquidity (current assets / current liabilities) rose
✗not met: No additional shares (diluted share count did not rise)
✗not met: Gross margin higher than the prior year
✗not met: Revenue relative to total assets higher than the prior year
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.
In short
Light red: Revenue shrank over 5 years (−6.0% per year).
Light red: Net income (total) shrank over 5 years (−20.2% per year); per share −18.7% per year.
Light yellow: Net margin 13.1%, below the sector median (13.9%).
Light green: Debt not higher than usual in the sector.
Light green: Profit in each of the last 10 fiscal years.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
RevenueNet incomeNet margin (below)in USD
05B10B15B
2016Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 11.4B USD · Net income 3.7B USD · Net margin 32.3%
2017Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 12.3B USD · Net income 2.5B USD · Net margin 20.7%
2018Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 13.5B USD · Net income 4.4B USD · Net margin 32.9%
2019Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 14.4B USD · Net income 5.9B USD · Net margin 41.0%
2020Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 13.4B USD · Net income 4.0B USD · Net margin 29.8%
2021Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 11.0B USD · Net income 1.6B USD · Net margin 14.2%
2022Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 10.2B USD · Net income 3.0B USD · Net margin 29.9%
2023Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 9.8B USD · Net income 1.2B USD · Net margin 11.8%
2024Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 9.7B USD · Net income 1.6B USD · Net margin 16.9%
2025Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 9.9B USD · Net income 1.3B USD · Net margin 13.1%
Margin
32%21%33%41%30%14%30%12%17%13%
RevenueNet incomeNet margin (below)in USD
01B2B3B
Q4/23Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Revenue 2.4B USD · Net income 249.7M USD · Net margin 10.5% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/24Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Revenue 2.3B USD · Net income 393.4M USD · Net margin 17.2%
Q2/24Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Revenue 2.5B USD · Net income 583.6M USD · Net margin 23.7%
Q3/24Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Revenue 2.5B USD · Net income 388.5M USD · Net margin 15.8%
Q4/24Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Revenue 2.5B USD · Net income 266.7M USD · Net margin 10.9% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/25Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Revenue 2.4B USD · Net income 240.5M USD · Net margin 9.9%
Q2/25Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Revenue 2.6B USD · Net income 634.8M USD · Net margin 24.0%
Q3/25Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Revenue 2.5B USD · Net income 466.5M USD · Net margin 18.4%
Q4/25Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Revenue 2.3B USD · Net income −48.9M USD · Net margin −2.1% · Q4 derived (year minus 9 months), may be distorted by restatements
Q1/26Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Revenue 2.5B USD · Net income 319.5M USD · Net margin 12.9%
Q2/26Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Revenue 2.7B USD · Net income 97.5M USD · Net margin 3.6%
Q3/26Quarter Q3/26 (Jul 1, 2026 – Sep 30, 2026): Revenue 2.8B USD · Net income −20.6M USD · Net margin −0.7%
Margin
10%17%24%16%11%9.9%24%18%−2.1%13%3.6%−0.7%
Earnings per shareUSD per share
010203040
2016Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Earnings per share 16.93 USD
2017Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Earnings per share 11.92 USD
2018Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Earnings per share 21.58 USD
2019Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Earnings per share 31.42 USD
2020Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Earnings per share 24.80 USD
2021Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Earnings per share 10.40 USD
2022Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Earnings per share 20.87 USD
2023Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Earnings per share 7.97 USD
2024Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Earnings per share 11.18 USD
2025Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Earnings per share 8.79 USD
Earnings per shareUSD per share
02.004.006.00
Q4/23Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Earnings per share not reported separately for Q4
Q1/24Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Earnings per share 2.70 USD
Q2/24Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Earnings per share 4.00 USD
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 9.9B USD · Net income 1.3B USD · Net margin 13.1%
How has it gone since the last annual report?
Trailing 12 months and quarters
Trailing 12 monthsFigures for the latest twelve months: fiscal year plus the months since it ended minus the same months a year earlier, each from the first SEC filing. More current than the fiscal year, but not audited. P/E, PEG and the checks still use the fiscal year.Example: Fiscal year $400M, 9 months after it $330M, same 9 months a year earlier $300M → 400 + 330 − 300 = $430M.More in the Academy: Lesson trailing twelve months
Revenue in the quarter to Sep 2026 +10.6% vs. the same quarter a year earlier; grown for 3 quarters in a row.
Revenue 12 months vs. prior 12Trailing 12 monthsFigures for the latest twelve months: fiscal year plus the months since it ended minus the same months a year earlier, each from the first SEC filing. More current than the fiscal year, but not audited. P/E, PEG and the checks still use the fiscal year.Example: Fiscal year $400M, 9 months after it $330M, same 9 months a year earlier $300M → 400 + 330 − 300 = $430M.More in the Academy: Lesson trailing twelve months
Free cash flow margin 12 monthsFree cash flowCash from operations minus investment in property, plant and equipment. It shows how much money is left over – for repaying debt, dividends or share repurchases.Example: Operating cash flow 120 million euros, investments 45 million euros → free cash flow 75 million euros.More in the Academy: Guide fundamental analysis
20.1%
Fiscal year 2025: 20.7%
More depth
Calculation of the 12 months to Sep 30, 2026
Revenue: fiscal year to Dec 31, 2025 9.9B USD + year to date to Sep 30, 2026 8.0B USD − same period a year earlier to Sep 30, 2025 7.6B USD = 10.3B USD
Net income: fiscal year to Dec 31, 2025 1.3B USD + year to date to Sep 30, 2026 396.4M USD − same period a year earlier to Sep 30, 2025 1.3B USD = 347.5M USD
Operating cash flow: fiscal year to Dec 31, 2025 2.2B USD + year to date to Sep 30, 2026 1.7B USD − same period a year earlier to Sep 30, 2025 1.7B USD = 2.2B USD
Capital expenditure: fiscal year to Dec 31, 2025 153.8M USD + year to date to Sep 30, 2026 132.5M USD − same period a year earlier to Sep 30, 2025 109.9M USD = 176.4M USD
By quarter (latest first, amounts in USD)
Quarter
Revenue
vs. year ago
Net income
Margin
Jul–Sep 26
2.8B
+10.6%
−20.6M
−0.7%
Apr–Jun 26
2.7B
+3.4%
97.5M
3.6%
Jan–Mar 26
2.5B
+1.9%
319.5M
12.9%
Oct–Dec 25*
2.3B
−7.1%
−48.9M
−2.1%
Jul–Sep 25
2.5B
+2.8%
466.5M
18.4%
Apr–Jun 25
2.6B
+7.3%
634.8M
24.0%
Jan–Mar 25
2.4B
+6.1%
240.5M
9.9%
Oct–Dec 24*
2.5B
+2.9%
266.7M
10.9%
Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.
Each quarter is compared with the same quarter a year earlier.
* derived: fiscal year minus the first 9 months.
As of: 12 months to Sep 30, 2026, filed on Oct 28, 2026 · Source: SEC filings (10-Q, 10-K)
Does the profit arrive as cash?
Earnings quality
Profit is backed by cash; interest is well covered.
Cash flow ÷ profitCash flow ÷ profitOperating cash flow divided by group profit. From 1.0, at least as much cash came in as profit was reported; below that, profit may sit in receivables or inventories, and non-cash gains or one-off payments also push the ratio down. Depreciation and stock-based pay lift it.Example: Operating cash flow €120m, group profit €100m → 1.20x.More in the Academy: Lesson earnings quality
1.71x
0.81.0
backed from 1.0 · 3 years: 1.62x
Interest coverageInterest coverageOperating income divided by interest expense: how many times the core business earns its interest. From 5x we count interest as well covered, below 2x as thinly covered.Example: Operating income €50m, interest expense €5m → 10.0x.More in the Academy: Lesson earnings quality
6.8x
25
well covered from 5 · EBIT, derived · 3 years: 7.2x
Tax rateTax rateIncome taxes divided by profit before tax, in percent. If the SEC data lack it, we approximate it as group profit plus taxes; minority interests, discontinued operations, one-off items and tax credits can shift the rate.Example: Taxes €21m, net income €79m → 21 : 100 = 21%.More in the Academy: Lesson earnings quality
16.9%
for information only · 3 years: 14.1%
More depth
Calculation for fiscal year 2025
Operating cash flow 2.2B USD ÷ Net income 1.3B USD = 1.71x
EBIT, derived (profit before tax plus interest expense) 1.8B USD ÷ Interest expense 267.5M USD = 6.8x
How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.
Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.
As of fiscal year 2025 · Source: SEC filings
How even were the last years?
Consistency
In 10 fiscal years no loss year and 5 years with lower revenue.
Loss yearsLoss yearsFiscal years that ended with a loss on the bottom line (net income below zero). Few loss years over a long period show how evenly a company has earned so far – they say nothing about the future.Example: Loss only in fiscal year 2020 → 1 of 10.More in the Academy: Lesson revenue, profit and margin
0 of 10
net income below zero
Years with lower revenueYear with lower revenueA fiscal year in which revenue was lower than in the prior year. Only years for which the prior year’s revenue is also reported are counted.Example: Revenue 100 → €96m → one year with lower revenue.More in the Academy: Lesson revenue, profit and margin
5 of 10
revenue below the prior year
Net margin rangeNet margin rangeHighest minus lowest net margin of the fiscal years shown, in percentage points. A small range means the share of profit in revenue stayed similar over the years.Example: Net margins between 18.2% and 26.4% → range 8.2 percentage points.More in the Academy: Lesson revenue, profit and margin
29.2 percentage points
from 11.8% to 41.0%
▾▾▾▾▾20162025Net margin by fiscal year · ▾ revenue below the prior yearMore depth
By fiscal year
FY
Revenue vs. prior year
Net margin
2025
+2.2%
13.1%
2024
−1.6%
16.9%
2023
−3.3%
11.8%
2022
−7.4%
29.9%
2021
−18.3%
14.2%
2020
−6.5%
29.8%
2019
+6.9%
41.0%
2018
+9.6%
32.9%
2017
+7.2%
20.7%
2016
+6.4%
32.3%
Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.
As of fiscal years 2016–2025 · Source: SEC filings
Figures over time
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Money flow in fiscal year 2025
Of 100 USD of revenue, 75.7 USD gross profit and 13.1 USD net income remained.
2016Fiscal year 2016: Operating cash flow 4.5B USD · Capital expenditure 616.1M USD · Free cash flow 3.9B USD
2017Fiscal year 2017: Operating cash flow 4.6B USD · Capital expenditure 867.4M USD · Free cash flow 3.7B USD
2018Fiscal year 2018: Operating cash flow 6.2B USD · Capital expenditure 770.6M USD · Free cash flow 5.4B USD
2019Fiscal year 2019: Operating cash flow 7.1B USD · Capital expenditure 514.5M USD · Free cash flow 6.6B USD
2020Fiscal year 2020: Operating cash flow 4.2B USD · Capital expenditure 424.8M USD · Free cash flow 3.8B USD
2021Fiscal year 2021: Operating cash flow 3.6B USD · Capital expenditure 258.1M USD · Free cash flow 3.4B USD
2022Fiscal year 2022: Operating cash flow 1.4B USD · Capital expenditure 240.3M USD · Free cash flow 1.1B USD
2023Fiscal year 2023: Operating cash flow 1.5B USD · Capital expenditure 277.0M USD · Free cash flow 1.3B USD
2024Fiscal year 2024: Operating cash flow 2.9B USD · Capital expenditure 153.7M USD · Free cash flow 2.7B USD
2025Fiscal year 2025: Operating cash flow 2.2B USD · Capital expenditure 153.8M USD · Free cash flow 2.1B USD
Share count
The share count fell in 5 years by 8.8% (mostly through share repurchases).
Diluted share count
0100M200M300M
2016Fiscal year 2016: Diluted share count 218.8M
2017Fiscal year 2017: Diluted share count 213.0M
2018Fiscal year 2018: Diluted share count 205.3M
2019Fiscal year 2019: Diluted share count 187.4M
2020Fiscal year 2020: Diluted share count 161.3M
2021Fiscal year 2021: Diluted share count 149.6M
2022Fiscal year 2022: Diluted share count 146.0M
2023Fiscal year 2023: Diluted share count 145.6M
2024Fiscal year 2024: Diluted share count 145.9M
2025Fiscal year 2025: Diluted share count 147.1M
From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
Metrics chart
Metrics chartUp to three metrics stacked, each with its own axis, over the same fiscal years. Optionally a second stock (dashed or hatched) and today’s sector median as a mark in the latest year – we do not have earlier medians.Example: Revenue rises, net margin falls, share count falls → more business, less profit per unit of revenue, fewer shares (mostly through buybacks).More in the Academy: Guide fundamental analysis
Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.
Net margin
The net margin fell in 5 years from 29.8% to 13.1%.
BIIBSector today 13.2%Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.
0%20%40%60%
2016Fiscal year 2016: BIIB 32.3%
2017Fiscal year 2017: BIIB 20.7%
2018Fiscal year 2018: BIIB 32.9%
2019Fiscal year 2019: BIIB 41.0%
2020Fiscal year 2020: BIIB 29.8%
2021Fiscal year 2021: BIIB 14.2%
2022Fiscal year 2022: BIIB 29.9%
2023Fiscal year 2023: BIIB 11.8%
2024Fiscal year 2024: BIIB 16.9%
2025Fiscal year 2025: BIIB 13.1% · Sector today 13.2%
Return on equity
Return on equity fell in 5 years from 37.4% to 7.1%.
BIIBSector today 13.6%
0%20%40%60%
2016Fiscal year 2016: BIIB 30.5%
2017Fiscal year 2017: BIIB 20.1%
2018Fiscal year 2018: BIIB 34.0%
2019Fiscal year 2019: BIIB 44.1%
2020Fiscal year 2020: BIIB 37.4%
2021Fiscal year 2021: BIIB 14.3%
2022Fiscal year 2022: BIIB 22.7%
2023Fiscal year 2023: BIIB 7.8%
2024Fiscal year 2024: BIIB 9.8%
2025Fiscal year 2025: BIIB 7.1% · Sector today 13.6%
Free cash flow margin
The free cash flow margin fell in 5 years from 28.3% to 20.7%.
BIIBSector today 15.8%
0%20%40%60%
2016Fiscal year 2016: BIIB 34.1%
2017Fiscal year 2017: BIIB 30.0%
2018Fiscal year 2018: BIIB 40.3%
2019Fiscal year 2019: BIIB 45.7%
2020Fiscal year 2020: BIIB 28.3%
2021Fiscal year 2021: BIIB 30.8%
2022Fiscal year 2022: BIIB 11.2%
2023Fiscal year 2023: BIIB 12.9%
2024Fiscal year 2024: BIIB 28.1%
2025Fiscal year 2025: BIIB 20.7% · Sector today 15.8%
Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.
How reliable is the dividend?
Dividend at a glance
The company pays no dividend.
As of fiscal year 2025 · Source: SEC filings
Valued higher or lower than usual?
Valuation against its own history
Valuation against its own historyWhere P/E, P/S or price/free cash flow stands today compared with the median of the company’s own last 5 fiscal years, in percent. Up to 10% deviation counts as “about at the median”. Describes only the position, not a judgement on an appropriate price.Example: P/E today 22, own 5-year median 27 → 22 ÷ 27 − 1 = −18.5%, so below the median.More in the Academy: Lesson cheaper or pricier than usual?
The P/E is above its own median of the 5 fiscal years before.
With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation.Sign up free
Source: SEC filings and our daily candles
Dividends and share repurchases
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
Dividend per share
nonepays no dividend
To shareholders (4 years)
2.6B USD100% through repurchases
Share count over 5 years
−8.8%fewer shares – each share is a larger stake
What goes back to shareholders
Over 4 years, 2.6B USD went back to shareholders, 100% of it through share repurchases. That is 30% of the free cash flow of those years.
2016Fiscal year 2016: Dividends paid not available · Share repurchases 1.0B USD · New shares issued (including employee plans) not available · Free cash flow 3.9B USD
2017Fiscal year 2017: Dividends paid not available · Share repurchases 1.4B USD · New shares issued (including employee plans) not available · Free cash flow 3.7B USD
2018Fiscal year 2018: Dividends paid not available · Share repurchases 4.4B USD · New shares issued (including employee plans) not available · Free cash flow 5.4B USD
2019Fiscal year 2019: Dividends paid not available · Share repurchases 5.9B USD · New shares issued (including employee plans) not available · Free cash flow 6.6B USD
2020Fiscal year 2020: Dividends paid not available · Share repurchases 6.7B USD · New shares issued (including employee plans) not available · Free cash flow 3.8B USD
2021Fiscal year 2021: Dividends paid not available · Share repurchases 1.8B USD · New shares issued (including employee plans) not available · Free cash flow 3.4B USD
2022Fiscal year 2022: Dividends paid not available · Share repurchases 750.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.1B USD
2023Fiscal year 2023: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 1.3B USD
2024Fiscal year 2024: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 2.7B USD
2025Fiscal year 2025: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 2.1B USD
Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Valuation over time
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.Log in
Sector comparison
Biogen next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.
Sector comparison BIIB, sector Health Care; last row: sector median
Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light red: shrinking
−6.0%per year, last 5 years
Sector Health Care: median +8.5% (25 symbols)
What does this mean? Revenue: over 5 years it fell by 6.0% per year on average. The median company in the sector reached +8.5% per year.
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light red: shrinking
−20.2%per year, last 5 years
Sector Health Care: median +5.5% (20 symbols)
per share: −18.7% per year (5 years, split-adjusted)
What does this mean? Total net income: over 5 years it fell by 20.2% per year on average. The median company in the sector reached +5.5% per year.
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
What does this mean? Of every 100 USD in revenue, 13.07 USD remained as profit – less than the median company in the sector (13.9%). Five years ago the margin was 29.8%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth
Light green: lower than sector
0.39latest balance sheet
Sector Health Care: median 0.66 (19 symbols)
What does this mean? For every 1 USD of equity there is 0.39 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth
Light gray: none found
–Dividend / earnings per share
Sector Health Care: median 56% (16 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin
Light green: profit every year
10 of 10fiscal years with a profit
What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
Last fiscal year and 13F
Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
9.9B USD
Revenue vs. prior year
+2.2%
Net income (FY)
1.3B USD
Net income vs. prior year
−20.8%
EPS (FY)
8.79 USD
Superinvestors holding
3 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 6, 2026 · Balance sheet Sep 30, 2026 (filed Oct 28, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term).Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
Year
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
2025
Dec 31, 2025
9.9B
1.3B
13.1%
8.79
–
–
2024
Dec 31, 2024
9.7B
1.6B
16.9%
11.18
–
–
2023
Dec 31, 2023
9.8B
1.2B
11.8%
7.97
–
–
2022
Dec 31, 2022
10.2B
3.0B
29.9%
20.87
–
–
2021
Dec 31, 2021
11.0B
1.6B
14.2%
10.40
–
–
2020
Dec 31, 2020
13.4B
4.0B
29.8%
24.80
–
–
2019
Dec 31, 2019
14.4B
5.9B
41.0%
31.42
–
–
2018
Dec 31, 2018
13.5B
4.4B
32.9%
21.58
–
–
2017
Dec 31, 2017
12.3B
2.5B
20.7%
11.92
–
–
2016
Dec 31, 2016
11.4B
3.7B
32.3%
16.93
–
–
Quarters (amounts in USD, per share in USD)
Quarter
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
Q3/26
Sep 30, 2026
2.8B
−20.6M
−0.7%
−0.14
–
–
Q2/26
Jun 30, 2026
2.7B
97.5M
3.6%
0.66
–
–
Q1/26
Mar 31, 2026
2.5B
319.5M
12.9%
2.15
–
–
Q4/25*
Dec 31, 2025
2.3B
−48.9M
−2.1%
–
–
–
Q3/25
Sep 30, 2025
2.5B
466.5M
18.4%
3.17
–
–
Q2/25
Jun 30, 2025
2.6B
634.8M
24.0%
4.33
–
–
Q1/25
Mar 31, 2025
2.4B
240.5M
9.9%
1.64
–
–
Q4/24*
Dec 31, 2024
2.5B
266.7M
10.9%
–
–
–
Q3/24
Sep 30, 2024
2.5B
388.5M
15.8%
2.66
–
–
Q2/24
Jun 30, 2024
2.5B
583.6M
23.7%
4.00
–
–
Q1/24
Mar 31, 2024
2.3B
393.4M
17.2%
2.70
–
–
Q4/23*
Dec 31, 2023
2.4B
249.7M
10.5%
–
–
–
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Information only – does not affect the other analysis methods, not investment advice.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary
Insider purchases and sales on the market over 3, 6 and 12 months
Period
Purchases
Sales
Net
3 months
$00 people
$00 people
$0
6 months
$00 people
$239.7K1 person
−$239.7K
12 months
$585.11 person
$905.4K2 people
−$904.8K
Latest transactions
Aug 4, 2026Minor LloydDirectorOpen-market sale · 10b5-1 plan593 shares · $119.2K · SEC
Aug 3, 2026Minor LloydDirectorOpen-market sale · 10b5-1 plan593 shares · $120.6K · SEC
Feb 12, 2026Murphy NicoleOfficerOpen-market purchase3 shares · $585.1 · SEC
Feb 9, 2026Singhal PriyaOfficerOpen-market sale · 10b5-1 plan2,660 shares · $531.5K · SEC
Feb 2, 2026Singhal PriyaOfficerOpen-market sale · 10b5-1 plan748 shares · $134.1K · SEC
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Which superinvestors hold Biogen?
Form 13F filingInvestment managers with discretion over at least 100 million USD in reportable US securities (mainly stocks and ETFs, plus options and convertible bonds) report their holdings to the SEC within 45 days after each quarter. Short positions, securities traded only abroad and cash are not included.Example: Positions as of 30 Sep, filed on 14 Nov → they are already six weeks old when published.More in the Academy: Glossary
Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.
Trend score –
We do not calculate a trend score for symbols in the extended universe.
Volatility and trend strength
ADX 14 (trend strength)–
Price change 60 days–
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.